Asia-Pacific Respiratory Device Market is estimated to grow $10.5 billion in 2027 from $6.9 billion in 2020, growing at a CAGR of 6.1% during the forecast period (2021-2027). Asia-Pacific region is considered to be the most emerging market due to the significant growth of the healthcare system in Asia-Pacific countries, such as India, China, and South Korea. Asia-Pacific region is forecast to witness immense growth due to significant investment by government and major market players, favorable government policies, and a high patient base. Asia-Pacific region covers more than 60% of the global population, has a high prevalence of respiratory diseases, such as asthma and COPD. These factors are expected to drive the growth of the market in the near future. Increasing air pollution in India is also one of the major causes of the growth of the respiratory device market.
To Request a Sample of our Report on Asia-Pacific Respiratory Device Market: https://www.omrglobal.com/request-sample/asia-pacific-respiratory-device-market
Growing Demand for Respiratory Device Market
The Asia-Pacific respiratory devices market presents future opportunities for growth as the prevalence of respiratory diseases such as asthma and COPD in emerging economies such as India and China. In addition, the increasing geriatric population specially in Japan is another major reason for the growing market.
(Get 15% Discount on Buying this Report)
A full Report of Asia-Pacific Respiratory Device Market is Available at: https://www.omrglobal.com/industry-reports/asia-pacific-respiratory-device-market
Scope of the Asia-Pacific Respiratory Device Market
Market Coverage
- The market number available – 2020-2027
- Base year- 2020
- Forecast period- 2021-2027
- Segment Covered- By Product, By End-User
- Regions Covered- Asia-Pacific (India, China, Japan, and Rest of Asia-Pacific)
- Competitive Landscape- Cipla Ltd., Novartis AG, Mylan N.V., Koninklijke Philips N.V., BMC Medical Co., Ltd.
Recent Strategic Initiatives in the Asia-Pacific Respiratory Device Market
- In May 2018, the company acquired NightBalance for expanding its sleep & respiratory care portfolio. The acquisition enables Philips Healthcare to expand its position in the home care market. In May 2017, Philips acquired the US-based RespirTech which provides solutions for chronic respiratory conditions such as pulmonary disease and cystic fibrosis. The acquisition enables the company to expand respiratory care, especially COPD patients with bronchiectasis.
- In January 2018, Resmed introduced Mobi which is a portable oxygen concentrator (POC). In May 2017, Resmed launched AirTouch F20 full face mask with UltraSoft memory for comfortable therapy of the patients. In January 2017 the company got FDA approval for AirMini. It is one of the smallest CPAP machines. In November 2016 Company launched AirFit N20 and AirFit F20 CPAP Masks.
Asia-Pacific Respiratory Device Market -Segmentation
By Product
- Respiratory Therapeutic Devices
- Respiratory Positive Airway Pressure Devices
- Respiratory Mask
- Respiratory Ventilators
- Respiratory Oxygen Concentrators
- Respiratory Inhalers
- Respiratory Resuscitators
- Respiratory Nebulizers
- Respiratory Humidifiers
- Respiratory Nitric Oxide Delivery Units
- Respiratory Oxygen Hoods
- Respiratory Diagnostic and Monitoring Devices
- Respiratory Pulse Oximeters
- Respiratory Capnography
- Respiratory Gas Analyzers
- Respiratory Spirometers
- Respiratory Polysomnography (PSG) Devices
- Respiratory Peak Flow Meters
- Respiratory Consumables and Accessories
- Respiratory Tracheostomy Tubes
- Respiratory Nasal Cannulas
- Respiratory Disposable Mask
- Respiratory Disposable Resuscitators
- Respiratory Other Consumables and Accessories
By End-User
- Hospitals
- Home Care
- Other End-Users
(This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.)
